More than 4,700 COVID-19 patients are in Ohio hospitals, the highest number of all of 2021 -- and hospitalization numbers are quickly approaching an all-time high, Gov. Mike DeWine's office said.

DeWine said he's calling up 1,050 National Guard members to help overwhelmed hospitals beginning on Monday.

The potential timeline for when children under 5 may have an authorized vaccine is now being pushed back.

Data for a two-shot vaccine was initially expected by the end of the year, but now Pfizer/BioNTech say they hope to have data with a third shot in the first half of 2022.

Pfizer/BioNTech said they "will amend the clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. The study will now include evaluating a third dose of 3 µg at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group."

An early look into the study data suggested that the two doses at a smaller volume was not as effective for kids ages 2 to 5 as it was for the 16 to 25 population, so scientists are going to add a third dose and see if the vaccine is as effective. There were no safety issues reported in the early data analysis.

Pfizer/BioNTech added in a statement, “The decision to evaluate a third dose of 3 µg for children 6 months to under 5 years of age reflects the companies’ commitment to carefully select the right dose to maximize the risk-benefit profile. If the three-dose study is successful, Pfizer and BioNTech expect to submit data to regulators to support an Emergency Use Authorization (EUA) for children 6 months to under 5 years of age in the first half of 2022.”

-ABC News' Eric M. Strauss

Americans in their 30s are accounting for the highest case rate of any age group, according to federal data.

The U.S. is now reporting nearly 120,000 new cases each day. The daily case average has surged by nearly 86.3% since late October, according to federal data.

Thirty-three states, as well as Washington, D.C., and New York City, have seen at least a 10% jump in daily cases over the last two weeks.

New Hampshire currently holds the nation's highest case rate, followed by Rhode Island, Maine, Wisconsin, Connecticut and Massachusetts, according to federal data.

-ABC News' Arielle Mitropoulos

White House COVID-19 response coordinator Jeff Zients warned Friday that the unvaccinated are "looking at a winter of severe illness and death -- for yourselves, your families and the hospitals you may soon overwhelm."

CDC director Rochelle Walensky said she expects omicron to become the dominant variant in the coming weeks.

Asked whether the CDC will change its guidance on vaccinated people quarantining after exposure, which they currently don't have to, Walensky said, "We are actively following the science in that area, with regard to how the viral burden is both among vaccinated people and unvaccinated people, and the natural history of that viral burden with regard to isolation."

"And as that science emerges, we will update our evidence if need be," she said.

-ABC News' Cheyenne Haslett

The omicron variant appears to have a "growth advantage" over the delta variant, the World Health Organization said in a technical brief released Sunday.

"It is spreading faster than the delta variant in South Africa where delta circulation was low, but also appears to spread more quickly than the delta variant in other countries where the incidence of delta is high, such as in the United Kingdom," the WHO said in the brief, which was dated Friday. "Whether omicron's observed rapid growth rate in countries with high levels of population immunity is related to immune evasion, intrinsic increased transmissibility, or a combination of both remains uncertain. However, given the current available data, it is likely that omicron will outpace the delta variant where community transmission occurs."

Meanwhile, preliminary findings from South Africa suggest omicron may cause less severe illness than delta, and all cases of omicron reported in Europe to date have been mild or asymptomatic. But the WHO said "it remains unclear to what extent omicron may be inherently less virulent" and that "more data are needed to understand the severity profile."

The WHO also noted that "there are limited available data, and no peer-reviewed evidence, on vaccine efficacy or effectiveness to date for omicron." However, preliminary evidence, and the considerably altered antigenic profile of the variant's spike protein, suggests a reduction in vaccine efficacy against infection and transmission associated with omicron.

"There is some preliminary evidence that the incidence of reinfection has increased in South Africa, which may be associated with humoral (antibody-mediated) immune evasion," the WHO said.

The diagnostic accuracy of routinely used polymerase chain reaction (PCR) test and antigen-based rapid diagnostic test (Ag-RDT) assays does not appear to be influenced by omicron. Therapeutic interventions for the management of severe or critical COVID-19 symptoms associated with omicron are also expected to remain effective, according to the WHO.

"However, monoclonal antibodies will need to be tested individually, for their antigen binding and virus neutralization and these studies should be prioritized," the WHO added.

-ABC News' Christine Theodorou